The CiPA Microelectrode Array Assay with hSC-Derived Cardiomyocytes: Current Protocol, Future Potential

  • Daniel C. Millard
  • Mike Clements
  • James D. Ross
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative, led by the US Food and Drug Administration (FDA), aims to improve preclinical cardiac safety evaluation and reduce unwarranted drug attrition by utilizing more comprehensive model systems. A major component of CiPA is the development of an electrophysiological assay using human stem cell-derived cardiomyocytes (hSC-CMs), which provide an integrated assessment of the multiple ion channels contributing to the cardiac action potential (AP). This chapter details the current CiPA protocol for evaluating drug-induced changes in hSC-CM electrophysiology using microelectrode array (MEA) technology. In this assay, electrodes embedded in a cell culture substrate noninvasively interface with established cardiomyocyte networks, providing functional, mechanistically based measures of the cardiac action potential without perturbing the cellular network. Introduction of multiwell MEA technology has significantly increased assay throughput, enabling development efforts that further demonstrate the predictivity and reliability of MEA assays for evaluation of cardiac safety liability. Following a review of MEA theory and the field potential (FP) signal, this chapter provides a step-by-step protocol for MEA plate preparation and maintenance, assay execution, and data analysis according to the current CiPA guidelines. Alternative approaches to the MEA assay are also discussed, along with commentary on emerging advances in MEA technology for the assessment of cardiac safety liability in vitro.

Key words

Cardiomyocyte Stem cell Microelectrode array Drug safety Field potential High throughput Multiwell Electrophysiology 

References

  1. 1.
    Thomas CA, Springer PA, Loeb GE, Berwald-Netter Y, Okun LM (1972) A miniature microelectrode array to monitor the bioelectric activity of cultured cells. Exp Cell Res 74(1):61–66CrossRefPubMedGoogle Scholar
  2. 2.
    Reppel M, Igelmund P, Egert U, Juchelka F, Hescheler J, Drobinskaya I (2007) Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 19(5–6):213–224PubMedGoogle Scholar
  3. 3.
    Meiry G, Reisner Y, Feld Y, Goldberg S, Rosen M, Ziv N, Binah O (2001) Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes. J Cardiovasc Electrophysiol 12(11):1269–1277CrossRefPubMedGoogle Scholar
  4. 4.
    Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, January CT (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301:2006–2017CrossRefGoogle Scholar
  5. 5.
    Clements M, Thomas N (2014) High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol Sci 140(2):445–461CrossRefPubMedGoogle Scholar
  6. 6.
    Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134(2):412–426CrossRefPubMedGoogle Scholar
  7. 7.
    Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Wu JC (2013) Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128(11 Suppl 1):S3–S13CrossRefPubMedGoogle Scholar
  8. 8.
    Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL (2010) Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4(2):107–116CrossRefPubMedGoogle Scholar
  9. 9.
    Gilchrist KH, Lewis GF, Gay EA, Sellgren KL, Grego S (2015) High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol Appl Pharmacol 288(2):249–257CrossRefPubMedGoogle Scholar
  10. 10.
    Spach MS, Barr RC, Serwer GA, Kootsey JM, Johnson EA (1972) Extracellular potentials related to intracellular action potentials in the dog Purkinje system. Circ Res 30(5):505–519CrossRefPubMedGoogle Scholar
  11. 11.
    Breckenridge LJ, Wilson RJ, Connolly P, Curtis AS, Dow JA, Blackshaw SE, Wilkinson CD (1995) Advantages of using microfabricated extracellular electrodes for in vitro neuronal recording. J Neurosci Res 42(2):266–276CrossRefPubMedGoogle Scholar
  12. 12.
    Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Sawada K (2015) Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 75:17–26CrossRefPubMedGoogle Scholar
  13. 13.
    Bove M, Grattarola M, Martinoia S, Verreschi G (1995) Interfacing cultured neurons to planar substrate microelectrodes: characterization of the neuron-to-microelectrode junction. Bioelectrochem Bioenerg 38(2):255–265CrossRefGoogle Scholar
  14. 14.
    Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32–45CrossRefPubMedGoogle Scholar
  15. 15.
    Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167(3):292–300CrossRefPubMedGoogle Scholar
  16. 16.
    Gintant, G. et al. (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat. Rev. Drug Discov., 15, 457–71Google Scholar
  17. 17.
    Nakamura, Y. et al. (2014) Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study. J. Pharmacol. Sci., 124, 494–501Google Scholar
  18. 18.
    Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Miyamoto N (2015) CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia—effects of 7 reference compounds at 10 facilities. J Pharmacol Toxicol Methods 78:93–102CrossRefPubMedGoogle Scholar
  19. 19.
    Clements M (2016) Multielectrode array (MEA) assay for profiling electrophysiological drug effects in human stem cell-derived cardiomyocytes. Curr Protoc Toxicol 68:22.4.1–22.4.32CrossRefGoogle Scholar
  20. 20.
    Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 8(9):1263–1268CrossRefPubMedGoogle Scholar
  21. 21.
    Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K (2011) Optogenetics in neural systems. Neuron 71(1):9–34CrossRefPubMedGoogle Scholar
  22. 22.
    Clements, I.P., Millard, D.C., Nicolini, A.M., Preyer, A.J., Grier, R., Heckerling, A., Blum, R.A., Tyler, P., McSweeney, K.M., Lu, Y.F. and Hall, D., 2016, March. Optogenetic stimulation of multiwell MEA plates for neural and cardiac applications. In SPIE BiOS (pp. 96902C-96902C). International Society for Optics and PhotonicsGoogle Scholar
  23. 23.
    Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, Stoelzle-Feix S, Becker N, Fertig N, January CT, Anson BD, Ross JD. (2016) Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes. Toxicol. Sci., kfw153Google Scholar
  24. 24.
    Clements M, Millar V, Williams AS, Kalinka S (2015) Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment. Toxicol Sci 148(1):241–260CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Daniel C. Millard
    • 1
  • Mike Clements
    • 2
  • James D. Ross
    • 1
  1. 1.Axion BioSystems, Inc.AtlantaUSA
  2. 2.Axion BioSystems, Inc.AtlantaUSA

Personalised recommendations